Ming-yuan Chen

This study tests a combination of three drugs (sintilimab, anlotinib, and chemotherapy) in 33 adults with recurrent or metastatic nasopharyngeal cancer that has not responded to prior immunotherapy. The goal is to see if this combo can shrink tumors or control the disease. Partic…

This phase 3 trial is testing whether adding a targeted drug (becotatug vedotin) to standard immunotherapy (a PD-1 inhibitor) before and after surgery can help people with a certain type of head and neck cancer live longer without the cancer coming back. About 430 adults with EGF…

This Phase 3 trial tests whether combining stereotactic body radiotherapy (SBRT) with the drug becotatug vedotin (MRG003) can improve outcomes for patients with EGFR-positive metastatic tumors that have spread to only a few spots (oligometastases). The study will enroll 200 adult…

This study is for people with advanced nasopharyngeal cancer (a type of throat cancer) whose tumors shrank significantly after initial chemotherapy and immunotherapy. It compares a lower dose of radiation therapy to the standard dose, both given with additional chemo and immunoth…

This study compares a lower dose of radiation (40.2Gy) to the standard dose (49.2Gy) for people with stage II nasopharyngeal cancer that responds well to chemotherapy. All participants also receive immunotherapy. The goal is to see if the lower dose can control the cancer just as…

This phase 3 trial tests whether giving less radiation to low-risk areas (reduced-target) is as effective as standard full-target radiation for patients with metastatic nasopharyngeal carcinoma who have already responded to chemotherapy and immunotherapy. The study involves 166 a…

This phase 2 trial tests four different drug combinations in 208 people with advanced nasopharyngeal cancer that has stopped responding to standard treatments, including immunotherapy. The goal is to see which combination best shrinks tumors and delays cancer growth. Participants…